KNOWLEDGE BANK

Interviews

ExpreS2ion Biotechnologies

Vice President - Business Development
ExpreSion Biotechnologies protein expression system ExpreS is an important protein expression tool in the scientists tool box for protein expression The ExpreS platform has demonstrated in many instances its usefulness in RD with several ExpreSmade proteins having now been crystallized

Articles

When Orphan Drugs Make All the Difference

Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan dru

Research Insights

Simulation-based Validation of a Method to Detect Changes in SARS-CoV-2 Reinfection Risk

Given the high global seroprevalence of SARSCoV understanding the risk of reinfection has become increasingly important Models developed to track trends in reinfection risk should be robust against possible biases arising from imperfect data

Case Studies

Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study

Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s

Techno Trends

Innovent Biologics Launches First-in-Class IGF-1R Monoclonal Antibody for Thyroid Eye Disease

Innovent Biologics has introduced SYCUME teprotumumab N as a groundbreaking IGFRtargeting antibody for thyroid eye disease TED marking Chinas first and the worlds second approved therapy of its kind

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Unlocking New Avenues in Cancer Therapy by Targeting Ubiquitin-Specific Proteases

Dr. Oon Chern Ein

Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.

2

Moving from Code to Consequence

Dr. Sanjesh Kumar

Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.

Dr. Disha Marwaha

Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.

3

Covid -19 and Nanoparticles

Ramendra Pati Pandey

Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.

 

Deepika

Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.

 

Reshma

Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.

 

Neehasri

Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.

 

5

How the Pharmaceutical Industry is Embracing a Technology-Driven Approach to Unlock New Growth Avenues

Nikkhil K Masurkar

Nikkhil K Masurkar, a research pharmacist with a dynamic entrepreneurial streak. Nikkhil K Masurkar is executive director of the ENTOD International Group - a leading specialty research-based pharma company specialising in ophthalmic, ENT and Dermatology medicines. As a third generation entrepreneur, Nikkhil took over his family’s three decade old pharmaceutical business. However, to ensure he was adequately prepared to lead the organisation into the 21st century, he delved deep into clinical pharmacy and pharmacy research for several years prior to it. He is a highly qualified research pharmacist from Kings College London (UK) with various clinical pharmacy and formulation research accreditations to his name. He also studied clinical pharmacy in Belfast and is also a member of the prestigious Royal Pharmaceutical Society in the UK. His strong leadership qualities, dynamic entrepreneurial spirit and sharp business acumen together with impressive pharmaceutical and research skills have enabled ENTOD to become one of the fastest growing speciality pharmaceutical companies in India and abroad.

 

press releasesRead more...

Asia–US Clinical Data Collaboration Built on IHH's Clinical Data

Mitsui Co Ltd Mitsui Head Office Tokyo President and CEO Kenichi Hori has entered a service agreement with Oncoshot Pte Ltd Oncoshot on the utilization of Oncoshots proprietary clinical

Teijin, Teijin Regenet and Shinshu University Hospital Launch Joint Research to Strengthen CAR-T Cell Therapy Manufacturing Capabilities in Japan

Teijin Limited Teijin Regenet Co Ltd and Shinshu University Hospital today announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene

VVMF, Australia’s First Viral Vector CDMO Receives TGA Manufacturing Licence

Viral Vector Manufacturing Facility Pty Ltd VVMF Australias first viral vector Contract Development and Manufacturing Organisation CDMO advises that the Therapeutic Goods Administration TGA

Oral insulin drug achieves a critical milestone

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

Transcenta Therapeutics HKEX a global clinicalstage biopharmaceutical company with fully integrated capabilities in discovery RD and process development of antibodybased therapeutics

1cBio and Lee's Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio's PARP1 Inhibitor OC-3 for Oncology in Greater China

cBio a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases and Lees Pharmaceutical

EventsRead more...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

CordenPharma Expands Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Annually

CordenPharma is expanding its sterile injectable manufacturing capacity at its Caponago site in Milan Italy through a multiyear investment programme

Exegenesis Bio Enters into Collaboration with Modalis to Advance MDL-201 for Duchenne Muscular Dystrophy

Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL an investigational treatment for Duchenne muscular dystrophy DMD

Schrödinger Forms Tectora Therapeutics to Advance Immunology and Inflammation Programmes

Schrdinger has announced the formation of Tectora Therapeutics The company was cofounded by Schrdinger New Enterprise Associates NEA and RA Capital Management

MannKind and Rose Pharma Partner to Develop Inhaled GLP-1 for Weight Management

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE Technosphere an investigational inhaled GLP therapy for weight management

Rezubio Advances RZ-520 into Phase 1 Clinical Trial Following FDA and NMPA Clearances

Rezubio has announced the first cohort dosing in its Phase clinical trial of RZ following Investigational New Drug IND clearances from the US Food and Drug Administration FDA and Chinas National Medical

ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease

Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients